B cells and antibodies in multiple sclerosis pathogenesis and therapy (Q38050398)

27 August 2017

B cells and antibodies in multiple sclerosis pathogenesis and therapy (English)

1 reference

27 August 2017

0 references

0 references

1 reference

Markus Krumbholz

1

1 reference

27 August 2017

Tobias Derfuss

series ordinal

2

1 reference

27 August 2017

Reinhard Hohlfeld

series ordinal

3

1 reference

27 August 2017

Edgar Meinl

series ordinal

4

1 reference

27 August 2017

language of work or name

English

0 references

publication date

9 October 2012

1 reference

27 August 2017

Nature Reviews Neurology

1 reference

27 August 2017

8

1 reference

27 August 2017

11

1 reference

27 August 2017

613-623

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2012.203

27 August 2017

0 references

cites work

Long-lived autoreactive plasma cells drive persistent autoimmune inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

B cells regulate autoimmunity by provision of IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Immunoglobulins and complement in postmortem multiple sclerosis tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Homogeneity of active demyelinating lesions in established multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Neurofascin as a novel target for autoantibody-mediated axonal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Lipid microarrays identify key mediators of autoimmune brain inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Identification of naturally occurring fatty acids of the myelin sheath that resolve neuroinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Potassium channel KIR4.1 as an immune target in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Relevance of immunological variables in neuroborreliosis and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

A unique antibody gene signature is prevalent in the central nervous system of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Inflammatory cortical demyelination in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Meningeal inflammation is not associated with cortical demyelination in chronic multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

The many roles of chemokines and chemokine receptors in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

21 January 2018

Cracking the BAFF code.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

B cell immunobiology in disease: evolving concepts from the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Depletion of B lymphocytes from cerebral perivascular spaces by rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Critical analysis of rituximab-induced serological changes in connective tissue diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Regulated expression of BAFF-binding receptors during human B cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

The discovery and development of belimumab: the anti-BLyS-lupus connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Atacicept: targeting B cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Identification of BLyS (B lymphocyte stimulator), a non-myelin-associated protein, as a functional ligand for Nogo-66 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Accelerated central nervous system autoimmunity in BAFF-receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

The anatomical and cellular basis of immune surveillance in the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Immunological markers of optimal response to natalizumab in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Finding a way out: lymphocyte egress from lymphoid organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Fingolimod is a potential novel therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

FTY720 suppresses humoral immunity by inhibiting germinal center reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

B lymphocytes exit lymph nodes through cortical lymphatic sinusoids by a mechanism independent of sphingosine-1-phosphate-mediated chemotaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Follicular shuttling of marginal zone B cells facilitates antigen transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

FTY720 in corneal concordant xenotransplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Induction of apoptosis by dexamethasone in the B cell lineage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Increased proliferation of blood mononuclear cells after plasmapheresis treatment of patients with demyelinating disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Effects of plasmapheresis on peripheral blood mononuclear cell populations from patients with macroglobulinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Anti-inflammatory actions of intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Vitamin D and autoimmune thyroid diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Effect of vitamin D(3) supplementation on peripheral B cell differentiation and isotype switching in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Smoking and disease progression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Environmental factors and their timing in adult-onset multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Smoking and multiple sclerosis: an updated meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Cigarette smoke-induced effects on bone marrow B-cell subsets and CD4+:CD8+ T-cell ratios are reversed by smoking cessation: influence of bone mass on immune cell response to and recovery from smoke exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

N-acetylcysteine increases the frequency of bone marrow pro-B/pre-B cells, but does not reverse cigarette smoking-induced loss of this subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Impact of female cigarette smoking on circulating B cells in vivo: the suppressed ICOSLG, TCF3, and VCAM1 gene functional network may inhibit normal cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Immunity 12 years after alemtuzumab in RA: CD5⁺ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

BAFF is increased in renal transplant patients following treatment with alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Alemtuzumab as compared to alternative contemporary induction regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Implication of perturbed axoglial apparatus in early pediatric multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Opposite effects of interferon-beta on new B and T cell release from production sites in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

The role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

The intrathecal, polyspecific antiviral immune response: Specific for MS or a general marker of CNS autoimmunity?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

The initiation and prevention of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Secondary lymphoid organ chemokines are elevated in the cerebrospinal fluid during central nervous system inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

CD49d blockade by natalizumab therapy in patients with multiple sclerosis increases immature B-lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Glucocorticoid-induced apoptosis in early B cells from human bone marrow.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Apoptosis of ileal Peyer's patch B cells is increased by glucocorticoids or anti-immunoglobulin antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Increased antibody production in peripheral blood mononuclear cells after plasma exchange therapy in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

BAFF is a biological response marker to IFN-beta treatment in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

BAFF is elevated in serum of patients with Wegener's granulomatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.203

31 March 2020

MS: is it one disease?

1 reference

12 December 2020

B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions

1 reference

12 December 2020

Spotlight on alemtuzumab.

1 reference

12 December 2020

Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS.

1 reference

12 December 2020

Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.

1 reference

12 December 2020

10.1038/NRNEUROL.2012.203

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

0 references

1 reference